Gene therapy for cardiomyopathy

Details Gene therapy for cardiomyopathy Gene therapy for cardiomyopathy

2006-01-24

2006-01-24

Li, Q. Janice (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S450000, C435S320100, C536S023100

Reexamination Certificate

active

06989374

ABSTRACT:
This invention enables the repair of cardiac function by noninvasive administration of an HGF gene in the form of Sendai virus (HVJ)-liposome into the affected cardiac muscle, thereby inducing angiogenesis of the cardiac muscle layer and repressing fibrosis.

REFERENCES:
patent: 5652225 (1997-07-01), Isner
patent: 5756122 (1998-05-01), Thierry et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5916193 (1999-06-01), Stevens et al.
patent: 6248722 (2001-06-01), Morishita et al.
patent: 0 461 560 (1997-07-01), None
patent: 1142590 (2001-10-01), None
patent: 2777678 (1998-07-01), None
patent: WO 91/06309 (1991-05-01), None
patent: WO 96/40062 (1996-12-01), None
patent: WO97/14307 (1997-04-01), None
patent: WO 97/07824 (1997-06-01), None
patent: WO99/36103 (1999-07-01), None
patent: WO 01/21214 (2001-03-01), None
patent: WO 01/32220 (2001-05-01), None
patent: WO 03/103721 (2003-12-01), None
Maurice et al, J Clin Invest Jul. 1999;104:21-9.
Robbins et al, Pharmcol Ther 1998;80:35-47.
Miller et al, FASEB J., vol. 9, pp. 190-199.
Deonarain, 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.
Kaneda et al, Mol. Med Today 1999;5:298-303.
Afione, et al., “Gene Therapy Vectors As Drug Delivery System,”Clin. Pharmacokinet.29(3):118-89, 1995.
Aoki, et al., “Beneficial Angiogenesis Induced By Over-Expression Of Human Hepatocyte Growth Factor (HGF) In Non-Infarcted And Infarcted Myocardium: Potential Gene Therapy For Myocardial Infarction,”Circulation98(17):1321 (1998).
Ardehali, et al., “Direct Gene Transfer Into Donor Hearts At The Time Of Harvest,” J. Thorac.Cardiovasc. Surg.109(4):716-20 (1995).
Baffour, et al., “Enhanced Angiogenesis And Growth Of Collaterals By In Vivo Administration Of Recombinant Basic Fibroblast Growth Factor In A Rabbit Model Of Acute Lower Limb Ischemia: Dose-Response Effect Of Basis Fibroblast Growth Factor,”Journal of Vascular Surgery16(3):181-91 (Aug. 1992).
Brittberg, et al., “Treatment Of Deep Cartilage Defects In The Knee With Autologous Chondrocyte Transplantation:,”The New England Journal of Medicine331(14):889-95 (Oct. 6, 1994).
Das, et al., “Molecular Targets Of Gene Therapy,”The Society of Thoracic Surgeons68:1929-33 (1999).
Esakof, et al., “Intraoperative Multiplane Transesophageal Echocardiography for Guiding Direct Myocardial Gene Transfer of Vascular Growth Factor in Patients with Refractory Angina Pecoris,”Hum. Gene Ther.10(14): 2307-14 (1999).
Folkman, et al., “Angiogenic Factors,”Science235:442-47 (Jan. 1987).
French, et al., “Direct In Vivo Gene Transfer Into Porcine Myocardium Using Replication-Deficient Adenoviral Vectors,”Circulation90:2414-24 (1994).
Grant, et al., “Scatter Factor Induces Blood Vessel Formation In Vivo,”Proc. Natl. Acad. Sci. USA90:1937-41 (1993).
Ishlkawa, et al., “Identification Of Angiogenic Activity And The Cloning And Expression Of Platelet-Derived Endothelial Cell growth Factor,”Nature338:557-62 (Apr. 1989).
Isner, et al., “Arterial Gene Therapy For Therapy For Therapeutic Angiogenesis In Patients With Peripheral Artery Disease,”Circulation91(11):2687-92 (1995).
Lin, et al., “Expression of Recombinant Genes in Myocardium In Vivo After Direct Injection of DNA,”Circulation82:2217-21 (1990).
Losordo, et al. “Gene Therapy For Myocardial Angiogenesis,”Circulationpp. 2800-2804 (1998).
Marshall, Eliot, “Gene Therapy's Growing Pains,”Science269:1050-55 (1995).
Miyazawa, et al., “Molecular Cloning And Sequence Analysis Of cDNA For Human Hepatocyte Growth Factor,”Biochemical and Biophyical Research Communications163(2):967-73 (1989).
Mulligan, Richard C., “The Basic Science Of Gene Therapy,”Science260:926-32 (May 1993).
Nabel, et al. “Recombinant Fibroblast Growth Factor-1 Promotes Intimal Hyperplasia And Angiogenesis In Artieries In Vivo,”Nature362:844-46 (Apr. 1993).
Nakamura, et al., “Partial Purification and Characterization of Hepatocyte Growth Factor From Serium of Hepatectomized Rats,”Biochem. Biophys. Res. Commun., 122:1450-59 (1983).
Nakamura, et al., “Purification and characterization of a growth factor, from rat platelets for mature parenchymal hepatyocytes in primary cultures,”Proc. Natl. Acad. Sci.USA 83:6489 (1986).
Nakamura, et al., “Molecular Cloning And Expression Of Human Hepatocyte Growth Factor,”Nature342:440-43 (1989).
Pu, et al., “Enhanced Revascularization Of The Ischemic Limb By Angiogenic Therapy,”Circulation88(1):208-15 (1993).
Riessen, et al., “Prospects For Site-Specific Delivery Of Pharmacologic And Molecular Therapies,”J. Am. Coll. Cardiol.23(5):1234-44 (1994.
Rowland, et al., “Potential Gene Therapy Strategies In The Treatment of Cardiovascular Disease,”Ann. Thorac. Surg.60:721-8 (1995).
Rosen, et al., “Scatter Factor (Hepatocyte Growth Factor) is a Potent Angogenesis Factor In Vivo,”Symp. Soc. Exp. Biol.47:227-234 (1993).
Schumacher, et al., “Induction Of Neoangiogenesis In Ischemic Myocardium By Human Growth Factors,”Circulation97:645-50 (1998).
Seki, et al., “Isolation And Expression Of cDNA For Different Forms Of Hepatocyte Growth Factor From HumanLeukocyte,”Biochemical and Biophyical Research Communications172(1)321-27 (1990).
Setoguchi, et al., “Stimulation Of Erythropoiesis By In Vivo Gene Therapy: Physiologic Consequences Of Transfer Of The Human Erythropoietin Gene To Experimental Animals Using An Adenovirus Vector,”The American Society of Hematology84(9):2946-53 (1994).
Shi, et al., “Expression Shut Down Following Direct Gene Transfer In The Coronary,”Circulation88(4): 2561 (1993).
Simons, et al., “Food For Starving Hearts,”Natural Medicine2(5):519-20 (1996).
Stratford-Perricaudet, et al., “Widespread Long-Term Gene Transfer To Mouse Skeletal Muscles And Heart,”J. Clin. Invest.90:626-30 (1992).
Takeshita, et al., “Therapeutic Angiogenesis: A single Intraarterial Bolas Of Vascular Endothelial Growth Factor Augments Revascularization In A Rabbit Ischemic Hind Limb Model,”J. Clin. Invest.93:622-70 (1994).
Tashiro et al., “Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues,”Proc. Natl. Acad. Sci.USA 87:3200 (1991).
Ueda, Hideki et al., “In Vivo Gene Transfection Of Hepatocyte Growth Factor Attenuates Ischemia-Reperfusion Injury In The Heart: Evidence For A Role Of HGF In Endogenous Myocardial Protection,”Abstracts From The 70thScientific Sessions3459:1-619.
Ueki, et al.,“Hepatocyte Growth Factor Gene Therapy Of Liver Cirrhosis In Rats,”Nature Medicine5(2): 226-30 (1999).
Van Belle, et al., “Potentiated Angiogenic Effect of Scatter Factor/Hepatocyte Growth Factor via Induction of Vascular Endothelial Growth Factor,”Circulation97(4):381-90 (1998).
Verma, et al., “Gene Therapy—Promises, Problems And Prospects,”Nature389:239-42 (1997).
Wakitani, et al, “Repair Of Rabbit Articular Surfaces With Allograft Chondrocytes Embedded In Collagen Gel,”The Journal of Bone and Joint Surgery71-B(1):74-80 (1989).
Wechsler, Andrew S., “Molecular Biology 101,”The Society of Thoracic Surgeons60:497-98 (1995).
“Antiogenesis Of Patients With Arteriosclerosis,” English Translation from theJapan Finanicial News Paper, Front Page(Dec. 14, 1998).
“Gene Therapy Taking Into View Recovery of Geriatric Disease,” English Translation From TheJapan Financial News Paper. Local News Section(Dec. 14, 1998).
“Gene Therapy Of Osaka University,” English Translation From TheAsahi News Paper(Nov. 2, 1999).
Nakamura et al., “Purification and subunit of hepatocyte growth factor form rat platelets.”FEBS Letter, vol. 224, No. 2, pp. 311-316, Nov. 1987.
Takeshita et al., “In Vivo E

Affiliated with

Also associated with

Rating

Gene therapy for cardiomyopathy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene therapy for cardiomyopathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene therapy for cardiomyopathy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3602781